<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399663</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among Children attending the Pediatric Hospital in Bamako, Mali (BamaCoV-Kids Study).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-4983012</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-4983012/v1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">This study aimed to assess the seroprevalence of SARS-CoV-2 among children attending pediatric consultations in Bamako, Mali, using a rapid diagnostic test (RDT) on fingertip or venous blood samples.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A single-center, prospective cross-sectional study was conducted from May to September 2022 at the Pediatric Hospital in Bamako, Mali. Children aged 1 to 15 years underwent phlebotomy or fingertip blood sampling for SARS-CoV-2 antibody testing using the Abbott Panbio COVID-19 IgG/IgM Test. Demographic data and potential risk factors were collected. Categorical variables were compared using Fisher's exact test, and quantitative variables were analyzed using the Mann-Whitney test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 315 children were included, with a median age of 6 years (range 3-9 years); 45.7% (144/315) were younger than 6 years, and 54% (170/315) were male. The majority lived in urban areas (89.9%) and used public transportation (85.7%). The overall seroprevalence was 63.5%, with a higher seroprevalence observed among children aged 6 years and older compared to those under 6 years. The odds of having a positive serology were approximately twice as high in children aged ≥6 years in both univariate (OR 1.99; 95% CI: 1.25-3.17; P=0.0014) and multivariable analyses (OR 2.05; 95% CI: 1.26-3.32; P=0.0038). No significant differences in seropositivity were found for other demographic or risk factors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A substantial proportion of children in Bamako showed evidence of past SARS-CoV-2 infection, underscoring the importance of continued surveillance and preventive measures in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maiga</LastName><ForeName>Almoustapha Issiaka</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Gabriel Touré.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodio</LastName><ForeName>Amadou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouedrago</LastName><ForeName>Salimata Alou</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldé</LastName><ForeName>Aliou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé publique (iPLESP).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dembele</LastName><ForeName>Penda</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traore</LastName><ForeName>Fatoumata Tata</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolo</LastName><ForeName>Oumar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Togo</LastName><ForeName>Josué</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, University of Sciences, Techniques and Technologies of Bamako.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulibaly</LastName><ForeName>Yacouba Aba</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Gabriel Touré.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylla</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Gabriel Touré.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Northwestern University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcelin</LastName><ForeName>Anne-Geneviève</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvez</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diakité</LastName><ForeName>Abdoul Aziz</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Gabriel Touré.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todesco</LastName><ForeName>Eve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 TW010350</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB027049</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">Anti-nucleocapsid antibodies</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">Mali</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword></KeywordList><CoiStatement>Competing interests None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399663</ArticleId><ArticleId IdType="pmc">PMC11469376</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-4983012/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-4983012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 cases |
WHO COVID-19 dashboard. Datadot
http://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Bullis S. S. M., Crothers J. W., Wayne S. &amp; Hale A. J. A cautionary tale of false-negative nasopharyngeal COVID-19 testing. IDCases 20, e00791 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199681</ArticleId><ArticleId IdType="pubmed">32377507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bwire G. et al. The COVID-19 pandemic in the African continent. BMC Med. 20, 167 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9059455</ArticleId><ArticleId IdType="pubmed">35501853</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 |
BMJ Global Health. https://gh.bmj.com/content/7/8/e008793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402450</ArticleId><ArticleId IdType="pubmed">35998978</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiga A. I. et al. High SARS-CoV-2 seroprevalence among health care workers in Bamako referral hospitals: a prospective multisite cross-sectional study (ANRS COV11). Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 28, 900–902 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848726</ArticleId><ArticleId IdType="pubmed">35182761</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeimi R. et al. SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. eClinicalMedicine 56, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9795163</ArticleId><ArticleId IdType="pubmed">36590788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara I. et al. Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study. medRxiv 2021.04.26.21256016 (2021) doi:10.1101/2021.04.26.21256016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.26.21256016</ArticleId><ArticleId IdType="pmc">PMC8394825</ArticleId><ArticleId IdType="pubmed">34185847</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 cases | WHO COVID-19 dashboard. datadot
https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Panbio COVID-19 IgG/IgM Rapid Test. https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-igg-igm-antibody-test.html.</Citation></Reference><Reference><Citation>Viner R. M. et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 175, 143–156 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519436</ArticleId><ArticleId IdType="pubmed">32975552</ArticleId></ArticleIdList></Reference><Reference><Citation>Madewell Z. J., Yang Y., Longini I. M. Jr, Halloran M. E. &amp; Dean N. E. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Netw. Open 3, e2031756 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737089</ArticleId><ArticleId IdType="pubmed">33315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake J. M. et al. A data-driven semi-parametric model of SARS-CoV-2 transmission in the United States. PLOS Comput. Biol. 19, e1011610 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10659176</ArticleId><ArticleId IdType="pubmed">37939201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward T. et al. Bayesian spatial modelling of localised SARS-CoV-2 transmission through mobility networks across England. PLoS Comput. Biol. 19, e1011580 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10756685</ArticleId><ArticleId IdType="pubmed">37956206</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutikov M. et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev.3, e13–e21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>